Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Gracell Approved for US Trial of FasTCAR in Early Multiple Myeloma

publication date: Jan 29, 2024

Gracell Biotech, a Suzhou-San Diego CAR-T company, was cleared to begin a US Phase 1 clinical trial of its FasTCAR next-day manufacturing candidate GC012F in the US as an early-line treatment of multiple myeloma (ELMM). It is the third U.S. IND clearance for GC012F, which is an autologous CAR-T candidate with a dual-targeting B cell maturation antigen (BCMA) and CD19. GC012F is currently being tested in multiple hematological cancer trials as well as autoimmune diseases. Gracell said it has demonstrated a consistently strong efficacy and safety profile. In December, Gracell announced it would be acquired by AstraZeneca for $1.2 billion. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital